Millenium cement restrictor:
This article was originally published in Clinica
Executive Summary
Millenium Biologix has received US FDA 510(k) clearance to market its Microporous Skelite resorbable cement restrictor for use in orthopaedic surgeries such as those involving the femoral and tibial canals in hip stem and total knee replacements. The implant is the first device based on the firm's Microporous Skelite technology to reach the market; the technology enables the development of specialised synthetic bone graft implants with greater compressive strength and impact resistance, claims the Kingston, Ontario firm.
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.